NasdaqGS:OLMABiotechs
Assessing Olema Pharmaceuticals (OLMA) Valuation After Analyst Upgrades And Recent Fundraising
Olema Pharmaceuticals (OLMA) is back in focus after a cluster of upbeat analyst actions and a recent capital raise highlighted investor interest in its breast cancer drug pipeline and funding position.
See our latest analysis for Olema Pharmaceuticals.
The 1 day share price return of 9.82% and 7 day share price return of 11.08% come after a sharp 90 day share price return of 165.66%. Recent analyst enthusiasm and a late 2025 equity raise have reinforced a story that has already produced a...